ACETYLCHOLINE RECEPTOR EPITOPES ON EPITHELIAL CELLS OF THYMOMA IN MYASTHENIA GRAVIS

The Lancet ◽  
1987 ◽  
Vol 329 (8526) ◽  
pp. 218 ◽  
Author(s):  
Thomas Kirchner ◽  
Florian Hoppe ◽  
HansKonrad Müller-Hermelink ◽  
Berthold Schalke ◽  
Socrates Tzartos
1992 ◽  
Vol 2 (2) ◽  
pp. 77-84 ◽  
Author(s):  
Alexander Marx ◽  
Mary Osborn ◽  
Socrates Tzartos ◽  
Kerstin I. Geuder ◽  
Berthold Schalke ◽  
...  

The coincidence of autoantibodies against the acetylcholine receptor (AChR) and muscle striational antigens (SA) is a characteristic finding in thymoma-associated myasthenia gravis (MG), but their origins are still unresolved. Some common muscle antigens that were shown to be targets of anti-SA autoantibodies in thymoma-associated MG have also been detected in normal or neoplastic thymic epithelial cells, suggesting that the release of (eventually altered) antigens from the thymic tumors could elicit SA autoimmunity. In contrast to this model, we report here that titin, which is a recently reported target of SA autoimmunity, is not expressed in thymomas. In addition, we show that skeletal muscle type-II fibers exhibit a striational immunoreactivity with monoclonal antibody mAb155, which was previously identified to label a very immunogenic cytoplasmic epitope of the AChR and neoplastic epithelial cells of MGassociated thymomas. We conclude from these findings that titin autoimmunity in thymoma-associated MG is either due to a molecular mimicry mechanism involving tumor antigens (other than titin) or is a secondary phenomenon following release of titin from muscle. Based on the common immunoreactivity of the AChR, a striational antigen and thymoma, we suggest as the pathogenetic mechanism of thymoma-associated MGa "circulus vitiosus" in which SA autoimmunity could help maintain the AChR autoimmunity that is primarily elicited by the thymomas.


1988 ◽  
Vol 540 (1 Advances in N) ◽  
pp. 554-556 ◽  
Author(s):  
TAKESHI SATO ◽  
YASUNORI ISHIGAKI ◽  
TADATOSHI KOMIYA ◽  
HIROSHI TSUDA

2021 ◽  
Author(s):  
Vasiliki Zouvelou ◽  
Maria Michail ◽  
Maria Belimezi ◽  
Paraskevi Zisimopoulou

2001 ◽  
Vol 59 (3B) ◽  
pp. 681-685 ◽  
Author(s):  
Maria da Penha A. Morita ◽  
Alberto A. Gabbai ◽  
Acary S.B. Oliveira ◽  
Audrey S. Penn

Myasthenia gravis (MG) in childhood is rare comprising 10 to 20 % of all myasthenic patients. We studied 18 patients with MG whose first symptoms started from 1 to 12 years of age, followed at the Department of Neurology of the UNIFESP-EPM, from January 1983 to August 1997. There were 10 girls and 8 boys (1.2:1). Eleven patients (61%) presented moderate or severe generalized disease and 4 (22%) had at least one myasthenic crisis. EMG with supramaximal repetitive nerve stimulation was diagnostic in 8 (47%) out of 17 patients, and chest CT was normal in 14 patients. Seropositivity to acetylcholine receptor antibodies was found in 81.6% (9 out of 11 tested) and the levels had no relation to clinical severity. Nine out of 16 patients (56%) worsened with pyridostigmine alone and were treated with prednisone. Four out of those nine continued worsening despite steroids and were subjected to thymectomy (all showed thymic lymphoid follicular hyperplasia). Three patients (75%) improved markedly after thymectomy and one (25%) worsened, eventually getting better with intravenous immunoglobulin and oral azathioprine. MG treatment, using all resources available, has to be individualized for each child.


Sign in / Sign up

Export Citation Format

Share Document